TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
Per Pfeiffer, Mette Yilmaz, Sören Möller, D. Zitnjak, Merete Krogh, Lone Nørgård Pétersen, Laurids Østergaard Poulsen, Stine Brændegaard Winther, Karina Gravgaard Thomsen, Camilla Qvortrup
Topics & Concepts
BevacizumabColorectal cancerOpen labelMedicineOncologyInternal medicineRandomized controlled trialCancerChemotherapyColorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGastric Cancer Management and Outcomes